These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 32504692)

  • 81. SAR and biological evaluation of 3-azabicyclo[3.1.0]hexane derivatives as μ opioid ligands.
    Lunn G; Roberts LR; Content S; Critcher DJ; Douglas S; Fenwick AE; Gethin DM; Goodwin G; Greenway D; Greenwood S; Hall K; Thomas M; Thompson S; Williams D; Wood G; Wylie A
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2200-3. PubMed ID: 22357342
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis.
    Fukuyama T; Ehling S; Cook E; Bäumer W
    J Pharmacol Exp Ther; 2015 Sep; 354(3):394-405. PubMed ID: 26159873
    [TBL] [Abstract][Full Text] [Related]  

  • 83. [Development of new topical substances for the treatment of atopic dermatitis].
    Freimooser S; Traidl S; Werfel T
    Dermatologie (Heidelb); 2022 Jul; 73(7):514-519. PubMed ID: 35608634
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The Neuropeptide Y Y
    Ma H; Gao T; Jakobsson JET; Weman HM; Xu B; Larhammar D; Lagerström MC
    J Pharmacol Exp Ther; 2020 Jan; 372(1):73-82. PubMed ID: 31771994
    [TBL] [Abstract][Full Text] [Related]  

  • 85. An approach to pruritus in atopic dermatitis: a critical systematic review of the tacrolimus ointment literature.
    Fleischer AB; Boguniewicz M
    J Drugs Dermatol; 2010 May; 9(5):488-98. PubMed ID: 20480792
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Mechanisms and treatment of opioid-induced pruritus: Peripheral and central pathways.
    Okutani H; Lo Vecchio S; Arendt-Nielsen L
    Eur J Pain; 2024 Feb; 28(2):214-230. PubMed ID: 37650457
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Chronic pruritus in the absence of specific skin disease: an update on pathophysiology, diagnosis, and therapy.
    Cassano N; Tessari G; Vena GA; Girolomoni G
    Am J Clin Dermatol; 2010 Dec; 11(6):399-411. PubMed ID: 20866115
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Chronic pruritus: targets, mechanisms and future therapies.
    Pogatzki-Zahn E; Marziniak M; Schneider G; Luger TA; Ständer S
    Drug News Perspect; 2008 Dec; 21(10):541-51. PubMed ID: 19221635
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Experimentally induced pruritus and cutaneous reactions with topical antihistamine and local analgesics in atopic eczema.
    Weisshaar E; Forster C; Dotzer M; Heyer G
    Skin Pharmacol; 1997; 10(4):183-90. PubMed ID: 9413892
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Topical Application of Angelica sinensis Improves Pruritus and Skin Inflammation in Mice with Atopic Dermatitis-Like Symptoms.
    Lee J; Choi YY; Kim MH; Han JM; Lee JE; Kim EH; Hong J; Kim J; Yang WM
    J Med Food; 2016 Jan; 19(1):98-105. PubMed ID: 26305727
    [TBL] [Abstract][Full Text] [Related]  

  • 91. The Future of Atopic Dermatitis Treatment.
    Patel N; Strowd LC
    Adv Exp Med Biol; 2017; 1027():185-210. PubMed ID: 29063440
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Possible Antipruritic Mechanism of Cyclosporine A in Atopic Dermatitis.
    Ko KC; Tominaga M; Kamata Y; Umehara Y; Matsuda H; Takahashi N; Kina K; Ogawa M; Ogawa H; Takamori K
    Acta Derm Venereol; 2016 Jun; 96(5):624-9. PubMed ID: 26671728
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Neuraxial opioid-induced itch and its pharmacological antagonism.
    Ko MC
    Handb Exp Pharmacol; 2015; 226():315-35. PubMed ID: 25861787
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Therapeutic management of atopic dermatitis.
    Jarrell L
    Nurse Pract; 2024 Jun; 49(6):39-46. PubMed ID: 38941080
    [TBL] [Abstract][Full Text] [Related]  

  • 95. [Pruritus in systemic diseases : Common and rare etiologies].
    Kremer AE; Mettang T
    Internist (Berl); 2019 Aug; 60(8):814-820. PubMed ID: 31243493
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Emerging Treatments and Novel Pathways in Pruritus.
    Besner Morin C; Misery L
    J Cutan Med Surg; 2019; 23(5):528-536. PubMed ID: 31167547
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Atopic Dermatitis: Managing the Itch.
    Farmer WS; Marathe KS
    Adv Exp Med Biol; 2024; 1447():191-207. PubMed ID: 38724794
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The anti-pruritic efficacy of TS-022, a prostanoid DP1 receptor agonist, is dependent on the endogenous prostaglandin D2 level in the skin of NC/Nga mice.
    Sugimoto M; Arai I; Futaki N; Hashimoto Y; Sakurai T; Honma Y; Nakaike S
    Eur J Pharmacol; 2007 Jun; 564(1-3):196-203. PubMed ID: 17328887
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Emerging small-molecule compounds for treatment of atopic dermatitis: a review.
    Vávrová K
    Expert Opin Ther Pat; 2016; 26(1):21-34. PubMed ID: 26470599
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys.
    Ko MC; Lee H; Song MS; Sobczyk-Kojiro K; Mosberg HI; Kishioka S; Woods JH; Naughton NN
    J Pharmacol Exp Ther; 2003 Apr; 305(1):173-9. PubMed ID: 12649366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.